Press release
Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025
CAMBRIDGE, MA / ACCESS Newswire / April 7, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple
About this update from Moderna, Inc.
[{"type":"text","content":"CAMBRIDGE, MA / ACCESS Newswire / April 7, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, influenza, respiratory syncytial virus (RSV), cytomegalovirus (CMV), norovirus, and mpox, at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Vienna, Austria, from April 11-15, 2025.Moderna will present twelve scientific presentations at the ESCMID 2025 Global Congress, including three oral presentations, one e-poster presentation, and eight poster presentations, highlighting the breadth of its research in respiratory and emerging infectious diseases.COVID-19Immunogenicity of JN.1- and KP.2-encoding mRNA COVID-19 vaccines against JN.1 SARS-CoV-2 sublineages in adult participants - Oral Presentation Presenter: Frances Priddy Session: Advances in vaccine effectiveness for viral respiratory infections Date: April 12 | Time & Location: 11:00 (Hall 9)Relative vaccine efficacy of a SARS-CoV-2 spike receptor-binding and N-terminal domain COVID-19 vaccine versus mRNA-1273: subgroup analyses - Oral Presentation Presenter: Spyros Chalkias Session: Vaccines and prophylaxis against respiratory viral infections Date: April 13 | Time & Location: 11:00 (Hall 9)Clinical evaluation of a SARS-CoV-2 spike receptor-binding and N-terminal domain COVID-19 vaccine - Poster Presentation Presenter: Spyros Chalkias Session: COVID-19 Date: April 12 | Time & Location: 12:00 (Poster Hall)Immunogenicity and safety of a SARS-CoV-2 N-terminal domain and receptor-binding domain monovalent XBB.1.5 vaccine in Japanese participants aged ≥12 years - Poster Presentation Presenter: Christina Grassi Session: COVID-19 Date: April 12 | Time & Location: 12:00 (Poster Hall)RSVSix-month Immunogenicity of mRNA-1345 RSV Vaccine in Adults Aged ≥60 Years - E-Poster Presentation Presenter: Mihir Desai Session: On the frontiers of vaccine-driven prevention Date: April 12 | Time & Location: 08:30 (Arena 1)Safety and immunogenicity of mRNA-1345 revaccination at 24 months in adults ≥60 years - Poster Presentation Presenter: Mihir Desai Session: Clinical Trials Date: April 15 | Time & Location: 12:00 (Poster Hall)Burden of chronic medical conditions that are risk factors for severe RSV among adults aged 18-59 years in the United States - Poste...